Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
Clinical trial NCT03919526 · COMPLETED
Trial details
- NCT number
- NCT03919526
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-11
- Primary completion
- 2023-11-01
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.